Citigroup Inc. has recently filed a preliminary pricing supplement for a new financial product, specifically 13-month autocallable contingent coupon securities linked to Boston Scientific Corporation (ticker: BSX). This filing, dated October 21, 2026, is significant as it reflects Citigroup's strategy to diversify its financial products and services.
Citigroup, a major player in the financial services sector, operates under the Standard Industrial Classification (SIC) of 6021, which pertains to National Commercial Banks. The company is listed on the New York Stock Exchange under the ticker symbols C, C-PN, and C-PR. Citigroup has a long history of providing a wide range of financial services, including investment banking, financial transaction services, and wealth management.
The filing indicates that the issuer of these new securities is Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc. The product is designed to offer investors a contingent coupon, which is contingent upon the performance of the underlying asset, Boston Scientific Corporation. The preliminary terms suggest that the securities will have a maturity date of December 9, 2027, and will pay a contingent coupon of 10.40% per annum, provided certain conditions are met.
According to the filing, the pricing date for these securities is set for November 4, 2026. This product aims to attract investors looking for potential returns linked to the performance of Boston Scientific, a company known for its medical device innovations.
The introduction of these securities could have implications for various stakeholders, including investors seeking new opportunities in the financial markets and competitors within the national commercial banking sector. Citigroup's move to launch these products may encourage other banks to enhance their own offerings to remain competitive.
The filing does not specify what happens next, but the upcoming pricing date will be crucial for determining the interest and uptake of these securities in the market.